| Patient | John Locke |
|---|---|
| Date of birth | 1632-09-08 |
| Identifiers | MRN HR-EN001-SYN-TD; SSN (made up) 000-01-8305 |
| Document date | 1692-03-26 |
| Author | Prudence Hartwell-Osei, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review of lung function and blood tests; pulmonology consultation today. [S]
Mr. Locke returns two weeks after his first visit. He has used albuterol once or twice a day, and not since early this morning, six hours before his tests. The open fires in his rooms have not been lit since his first visit; the household has put electric heaters in his study and bedroom, and a HEPA air cleaner runs in each. He has stayed in the country and checks the air quality index each morning. His night cough has eased to two nights a week, but he is still breathless on stairs and hills and wheezes in the cold. He has had no fever, weight loss, night sweats, or blood in his sputum. This morning he had full lung function tests, a six-minute walk, and a CT of the chest, and saw Dr. Nwankwo-Fairfax of pulmonology. [S]
| Element | Detail |
|---|---|
| Reliever use | Albuterol once or twice a day; withheld six hours before testing |
| Exposure | No open fires since intake; electric heating; HEPA air cleaners running; no city trips |
| Symptoms | Night cough two nights a week; breathless on stairs and hills |
| Asthma Control Test | 13, up from 12 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, night sweats, or weight loss |
| Ears, nose, mouth, and throat | Negative | No nasal blockage, postnasal drip, or loss of smell |
| Respiratory | Positive | Cough at night two nights a week, wheeze in cold air, breathless on exertion; no hemoptysis |
| Cardiovascular | Negative | No chest pain, ankle swelling, or breathlessness lying flat |
| Gastrointestinal | Negative | No heartburn or acid regurgitation |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Albuterol 90 mcg/actuation inhaler, two puffs every 4 hours as needed while tests are done; hold for 6 hours before spirometry | Two puffs every 4 hours as needed | Respiratory tract route | 1692-03-12 to 1692-03-26 | completed | S |
| Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 4): two inhalations twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a day | Two inhalations twice daily plus one as needed; no more than 12 a day | Respiratory tract route | 1692-03-26 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1692-03-26 | Body height | 178 | cm | S |
| 1692-03-26 | Body weight | 62.1 | kg | S |
| 1692-03-26 | Body mass index (BMI) [Ratio] | 19.6 | kg/m2 | S |
| 1692-03-26 | Systolic blood pressure | 120 | mm[Hg] | S |
| 1692-03-26 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1692-03-26 | Heart rate | 82 | /min | S |
| 1692-03-26 | Respiratory rate | 18 | /min | S |
| 1692-03-26 | Body temperature | 36.5 | Cel | S |
| 1692-03-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1692-03-26 | FEV1 --pre bronchodilation | 2.11 | L | Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 3.38 L | Low | S |
| 1692-03-26 | Forced vital capacity [Volume] Respiratory system by Spirometry --pre bronchodilation | 3.71 | L | Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 4.37 L | Normal | S |
| 1692-03-26 | FEV1/FVC | 0.57 | {ratio} | Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm | Low | S |
| 1692-03-26 | FEV1 measured/predicted | 62 | % | GLI Global race-neutral equations for a man of 59, 178 cm | Low | S |
| 1692-03-26 | FEV1 --post bronchodilation | 2.49 | L | Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 3.38 L | Low | S |
| 1692-03-26 | Forced vital capacity [Volume] Respiratory system --post bronchodilation | 4.02 | L | Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 4.37 L | Normal | S |
| 1692-03-26 | FEV1/FVC --post bronchodilation | 0.62 | {ratio} | Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; below it (and below 0.70) after bronchodilator means persistent airflow limitation | Low | S |
| 1692-03-26 | Diffusion capacity.carbon monoxide | 26.4 | mL/min/mm[Hg] | Lower limit of normal, GLI 1683 race-neutral equations; predicted 26.9 | Normal | S |
| 1692-03-26 | Fractional concentration of exhaled nitric oxide | 41 | [ppb] | In adults, below 25 ppb low, 25 to 50 intermediate, above 50 high (ATS) | High | S |
| 1692-03-26 | Six minute walk test | 430 | m | Predicted about 630 m for his age, sex, height and weight (Enright and Sherrill); lower limit about 480 m | Low | S |
| 1692-03-26 | Total score [ACT] | 13 | {score} | S |
Vital signs recorded on 1692-03-26; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Thin, comfortable at rest |
| Respiratory | Prolonged expiration with scattered expiratory wheeze; no crackles; no clubbing; oxygen saturation 95 percent |
| Cardiovascular | Regular rhythm; no murmur; jugular venous pressure not raised; no edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Chronic cough with wheeze and breathlessness since his late thirties, worse every winter and within a day of any stay in the city or by an open fire, better in warm weather and country air; night cough two or three times a week this winter; under evaluation | resolved | confirmed | R05.3 | S — Synthetic presenting problem echoing his documented lifelong cough and breathlessness in London's coal smoke; superseded by the diagnosis at the second visit. |
| Long exposure to urban air pollution (decades in a large city with heavy traffic and coal and wood burning) and to indoor solid-fuel smoke from open coal and wood fires at home | active | confirmed | Z77.110 | S — Synthetic modern exposure echoing the coal smoke that he, Sydenham, and Lady Masham blamed for his cough; no historical level of exposure is asserted. |
| Asthma with persistent airflow limitation, type 2 (eosinophilic) phenotype, in a never-smoker: post-bronchodilator FEV1/FVC 0.62, FEV1 62 percent predicted rising 380 mL after albuterol, FeNO 41 ppb, eosinophils 0.46 x 10^3/uL, IgE 186 IU/mL, normal DLCO, no emphysema on CT; aggravated by air pollution and indoor smoke; not COPD | active | confirmed | J45.40 | S — Synthetic modern diagnosis. His lifelong cough and breathlessness worse in coal smoke are documented (D); calling them asthma is a modern retrospective reading (R). |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Asthma Control Test | Every visit | Completed today | 13, up from 12; still very poorly controlled |
| Imaging | Spirometry before and after bronchodilator (FEV1, FVC, FEV1/FVC, bronchodilator response) | At diagnosis, 3 to 6 months after starting treatment, then every 1 to 2 years | Completed today | FEV1 2.11 L before (62 percent predicted) and 2.49 L after albuterol (+380 mL); FVC 3.71 L before and 4.02 L after; FEV1/FVC 0.57 before and 0.62 after, below the lower limit of normal; GLI Global race-neutral equations |
| Imaging | FeNO | When the diagnosis is uncertain, and to monitor inhaled-corticosteroid response | Completed today | 41 ppb, intermediate, before any inhaled corticosteroid |
| Imaging | Diffusing capacity (DLCO) | Once, for persistent airflow limitation | Completed today | 26.4 mL/min/mmHg, normal |
| Imaging | Six-minute walk test | Before and after pulmonary rehabilitation | Completed today | 430 m, below the lower limit of about 480 m; lowest saturation 94 percent |
| Laboratory | Blood eosinophils and total IgE | At diagnosis and at any severe-asthma workup | Completed today | Results from the first visit reviewed today: eosinophils 0.46 x 10^3/uL; IgE 186 IU/mL |
| Laboratory | Alpha-1 antitrypsin level | Once, for persistent airflow limitation | Completed today | Result from the first visit reviewed today: 131 mg/dL, normal |
| Imaging | Chest imaging (X-ray; CT) | Chest X-ray or CT only for atypical features or a suspected complication | Completed today | Chest X-ray at the first visit clear; CT today for persistent airflow limitation in a never-smoker: airway wall thickening and air trapping, no emphysema, bronchiectasis, or nodules |
| Examination | Inhaler technique with his own devices | Every visit | Completed today | Taught today with his new budesonide-formoterol inhaler; correct by teach-back |
| Medication safety | Adherence and reliever use | Every visit | Completed today | Albuterol once or twice a day until today, when it is stopped and replaced by budesonide-formoterol as needed |
| Survey | Exacerbation history (oral corticosteroid courses, emergency visits, admissions in the past 12 months) | Every visit | Completed today | None |
| Self-management | Trigger and exposure review: indoor solid-fuel smoke, outdoor air pollution and air quality alerts, tobacco and vaping, occupational exposures, allergens | Every visit | Completed today | Open fires out of use since intake; electric heating; HEPA air cleaners in his study and bedroom; air quality index checked each morning; no city trips since intake |
| Self-management | Smoking and vaping status | Every visit | Completed today | Never smoker; no vaping; no secondhand smoke |
| Self-management | Written asthma action plan | Every visit and after every flare | Completed today | First written plan given today, symptom-based; peak-flow zones to be added once his personal best is known |
| Medication safety | Step-up and step-down assessment | Every visit | Completed today | Started at GINA track 1, step 4 (medium-dose budesonide-formoterol maintenance and reliever) for very poorly controlled asthma with low lung function |
| Examination | Comorbidity surveillance: rhinitis and sinus disease, reflux, obesity, sleep apnea, vocal cord dysfunction, anxiety and depression | At diagnosis and at least yearly | Up to date | Screened at the first visit: no rhinitis, reflux, or snoring; BMI 19.6; PHQ-2 1 |
| Referral | Pulmonary rehabilitation | For persistent breathlessness or reduced exercise capacity | Ordered | Eight-week program starting next week |
| Referral | Pulmonology consultation | For diagnostic uncertainty or persistent airflow limitation | Completed today | Seen today; agrees with asthma with persistent airflow limitation and the plan |
| Self-management | Vaccination status | Yearly | Completed today | PCV20 today; influenza, COVID-19, and RSV vaccines due in the autumn; Tdap up to date |
| Medication safety | Biologic candidacy | When asthma is severe and uncontrolled despite optimized step 4 to 5 treatment with confirmed adherence and technique | Not indicated | No exacerbations needing oral corticosteroids and not uncontrolled on optimized treatment |
Goal progress:
Immunizations given today: Pneumococcal conjugate vaccine PCV20 [S]
Guideline basis: CMID: Clinical Monitoring Intelligence Database, asthma and COPD monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025); Stanojevic S, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022;60(1):2101499 (PMID 34949706) (2022); Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023); Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023); WHO global air quality guidelines: particulate matter (PM2.5 and PM10), ozone, nitrogen dioxide, sulfur dioxide and carbon monoxide (2021); Carlsten C, et al. Personal strategies to minimise effects of air pollution on respiratory health: advice for providers, patients and the public. Eur Respir J 2020;55(6):1902056 (PMID 32241830) (2020); AQI Basics (2026); Air Cleaners and Air Filters in the Home (2026); Adult Immunization Schedule by Age (2026)
Follow-up: Asthma review in twelve weeks with repeat spirometry and FeNO; call sooner if the reliever is needed more than usual. Next scheduled visit 1692-06-18: twelve-week asthma review with repeat spirometry after pulmonary rehabilitation. [S]